Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat

Neuropharmacology

Volumn 70, Issue , 2013, Pages 74-82

  Zengin Toktas, Yildiz ^a,b   Authier, Nicolas ^a,b   Denizot, Hélène ^a,b   Chassain, Carine ^a,b   Hafidi, Aziz ^a   Llorca, Pierre M ^a,b   Durif, Franck ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Cocaine; Conditioned place preference; Dopamine dysregulation syndrome; Dopamine receptor agonists; l dopa; Parkinson's disease

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BROMOCRIPTINE; COCAINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC SYSTEM; HABITUATION; LOCOMOTION; MOTIVATION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; ROTAROD TEST;

ANIMALS; COCAINE; CONDITIONING (PSYCHOLOGY); DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; LEVODOPA; MALE; MOTIVATION; MOTOR ACTIVITY; OXIDOPAMINE; RATS; RECEPTORS, DOPAMINE; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84876953689     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.12.011     Document Type: Article

References (68)

1. B.S. Abrahams, J.D. Rutherford, P.E. Mallet, and R.J. Beninger Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434 Eur. J. Pharmacol. 343 1998 111 118
2. D.J. Brooks, V. Ibanez, G.V. Sawle, E.D. Playford, N. Quinn, C.J. Mathias, A.J. Lees, C.D. Marsden, R. Bannister, and R.S. Frackowiak Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography Ann. Neurol. 31 1992 184 192
3. R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff, and J.C. Schwartz Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc. Natl. Acad. Sci. U. S. A. 94 1997 3363 3367
4. J.C. Corvol, M.P. Muriel, E. Valient, J. Féger, N. Hanoun, J.A. Girault, E.C. Hirsch, and D. Hervé Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease J. Neurosci. 24 2004 7007 7014
5. E. Courty, F. Durif, M. Zenut, P. Courty, and J. Lavarenne Psychiatric and sexual disorders induced by apomorphine in Parkinson disease Clin. Neuropharmacol. 20 1997 140 147
6. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity Science 197 1977 596 598
7. J. Diaz, C. Pilon, B. Le Foll, C. Gros, A. Triller, J.C. Schwartz, and P. Sokoloff Dopamine D3 receptors expressed by all mesencephalic dopamine neurons J. Neurosci. 20 2000 8677 8684
8. A. Dearry, J.A. Gingrich, P. Falardeau, R.T. Fremeau, M.D. Bates, and M.G. Caron Molecular cloning and expression of the gene for a human D1 dopamine receptor Nature 347 1990 72 76
9. J. De Keyser, J.P. De Backer, N. Wilczak, and L. Herroelen Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum Prog. Neuropsychopharmacol. Biol. Psychiatry 19 1995 1147 1154
10. T. De Paulis Sumanirole Pharmacia Curr. Opin. Investig. 4 2003 77 82
11. G. Emilien, J.M. Maloteaux, M. Geurts, K. Hoogenberg, and S. Cragg Dopamine receptors-physiological understanding to therapeutic intervention potential Pharmacol. Ther. 84 1999 133 156
12. A.H. Evans, and A.J. Lees Dopamine dysregulation syndrome in Parkinson's disease Curr. Opin. Neurol. 17 2004 393 398
13. S. Fenu, J. Wardas, and M. Morelli Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease Behav. Pharmacol. 20 2009 363 379
14. D.C. German, K. Manaye, W.K. Smith, D.J. Woodward, and C.B. Saper Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization Ann. Neurol. 26 1989 507 514
15. G. Giovannoni, J.D. O'Sullivan, K. Turner, A.J. Manson, and A.J. Lees Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies J. Neurol. Neurosurg. Psychiatry 68 2000 423 428
16. D.L. Graham, R. Hoppenot, A. Hendryx, and D.W. Self Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats Psychopharmacology 191 2007 719 730
17. O. Guillin, N. Griffon, J. Diaz, B. Le Foll, E. Bezard, C. Gross, C. Lammers, H. Stark, P. Carroll, J.C. Schwartz, and P. Sokoloff Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway Int. Rev. Neurobiol. 59 2004 425 444
18. M. Guttman, and P. Seeman L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's disease striatum J. Neural Transm. 64 1985 93 103
19. I. Gyertyán, and K. Gál Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference Neuroreport 14 2003 93 98
20. D. Hervé, M. Lévi-Strauss, I. Marey-Semper, C. Verney, J.P. Tassin, J. Glowinski, and J.A. Girault G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase J. Neurosci. 13 1993 2237 2248
21. T. Hnasko, B.N. Sotak, and R.D. Palmitier Cocaine-conditioned place preference by dopamine-deficient mice is mediated by serotonin J. Neurosci. 27 2007 12484 12488
22. M.M. Hoehn The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras Neurol. Clin. 10 1992 331 339
23. D.C. Hoffman, P.R. Dickson, and R.J. Beninger The dopamine D2 receptor agonists, quinpirole and bromocriptine produce conditioned place preferences Prog. Neuropsychopharmacol. Biol. Psychiatry 12 1988 315 322
24. A.J. Holman Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia J. Gambl. Stud. 25 2009 425 431
25. P. Jenner, S. Boyce, and C.D. Marsden Receptor changes during chronic dopaminergic stimulation J. Neural Transm. 27 1998 161 175
26. V. Kaasinen, H. Ruottinen, K. Nagren, P. Lehikoinen, V. Oikonen, and J.O. Rinne Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C]raclopride and [11C]N-Methylspiperone J. Nucl. Med. 41 2000 65 70
27. T.V. Khroyan, R.A. Fuchs, D.A. Baker, and J.L. Neisewander Effects of D3-preferring agonists 7-OH-PIPAT and PD-128,907 on motor behaviors and place conditioning Behav. Pharmacol. 8 1997 65 74
28. T. Kondo Dopamine dysregulation syndrome. Hypothetical application of reward system stimulation for the treatment of anhedonia in Parkinson's disease patients J. Neurol. 255 2008 14 18
29. M.J. Kuhar, M.C. Ritz, and J.W. Boja The dopamine hypothesis of the reinforcing properties of cocaine Trends Neurosci. 14 1991 299 302
30. A.D. Lawrence, A.H. Evans, and A.J. Lees Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol. 2 2003 595 604
31. T. Lee, P. Seeman, A. Rajput, I.J. Farley, and O. Hornykiewicz Receptor basis for dopaminergic supersensitivity in Parkinson's disease Nature 273 1978 59 61
32. B. Le Foll, S.R. Goldberg, and P. Sokoloff The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49 2005 525 541
33. D. Lévesque, M.P. Martres, J. Diaz, N. Griffon, C.H. Lammers, P. Sokoloff, and J.C. Schwartz A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons Proc. Natl. Acad. Sci. U. S. A. 92 1995 1719 1723
34. S. Maia, N. Arlicot, E. Vierron, S. Bodar, J. Vergote, D. Guilloteau, and S. Chalon Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease Synapse 66 2012 573 583
35. D. Marcellino, S. Ferré, V. Casado, A. Cortés, B. Le Foll, C. Mazzola, F. Drago, O. Saur, H. Stark, A. Soriano, C. Barnes, S.R. Goldberg, C. Lluis, K. Fuxe, and R. Franco Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum J. Biol. Chem. 283 2008 26016 26025
36. R.B. McCall, K.J. Lookingland, P.J. Bédard, and R.M. Huff Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease J. Pharmacol. Exp. Ther. 314 2005 1248 1256
37. D. Merims, and N. Giladi Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease Parkinsonism. Relat. Disord. 14 2008 273 280
38. M.J. Millan, S. Girardon, S. Monneyron, and A. Dekeyne Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors Neuropharmacology 39 2000 586 598
39. M. Morissette, M. Goulet, R. Grondin, P. Blanchet, P.J. Be'dard, T. Di Paolo, and D. Lévesque Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies Eur. J. Neurosci. 10 1998 2565 2573
40. J.K. Morris, G.L. Bomhoff, J.A. Stanford, and P.C. Geiger Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet Am. J. Physiol. Regul. Integr. Comp. Physiol. 299 2010 1082 1090
41. M.P. Muriel, G. Orieux, and E.C. Hirsch Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats Mov. Disord. 17 2002 1174 1179
42. J.L. Neumeyer, N.S. Kula, J. Bergman, and R.J. Baldessarini Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines Eur. J. Pharmacol. 474 2003 137 140
43. A. Newman-Tancredi, V. Audinot, V. Jacques, J.L. Peglion, and M.J. Millan [3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors Neuropharmacology 34 1995 1693 1696
44. V. Paillé, V. Henry, L. Lescaudron, P. Brachet, and P. Damier Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias Mov. Disord. 22 2007 533 539
45. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates second ed. 1986 Academic London
46. S. Perachon, J.C. Schwartz, and P. Sokoloff Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors Eur. J. Pharmacol. 366 1999 293 300
47. F.R. Pezzella, C. Colosimo, N. Vanacore, S. Di Rezze, M. Chianese, G. Fabbrini, and G. Meco Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease Mov. Disord. 20 2005 77 81
48. E.Y. Pioli, W. Meissner, R. Sohr, C.E. Gross, E. Bezard, and B.H. Bioulac Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats Neuroscience 153 2008 1213 1224
49. T.A. Pugsley, M.D. Davis, H.C. Akunne, R.G. MacKenzie, Y.H. Shih, G. Damsma, H. Wikstrom, S.Z. Whetzel, L.M. Georgic, L.W. Cooke, S.B. Demattos, A.E. Corbin, S.A. Glase, L.D. Wise, D. Dijkstra, and T.G. Heffner Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907 J. Pharmacol. Exp. Ther. 275 1995 1355 1366
50. A. Reches, H.R. Wagner, V. Jackson-Lewis, E. Yablonskaya-Alter, and S. Fahn Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum Neurology 34 1984 1208 1212
51. U.K. Rinne, A. Laihnen, J.O. Rinne, K. Någren, J. Bergman, and U. Ruotsalainen Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease Mov. Disord. 5 1990 55 59
52. H.L. Ryoo, D. Pierrotti, and J.N. Joyce Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease Mov. Disord. 13 1998 788 797
53. F. Sautel, N. Griffon, D. Lévesque, C. Pilon, J.C. Schwartz, and P. Sokoloff A functional test identifies dopamine agonists selective for D3 versus D2 receptors Neuroreport 6 1995 329 332
54. M. Savasta, A. Dubois, J. Benavidès, and B. Scatton Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission Neurosci. Lett. 85 1988 119 124
55. R.K. Schwarting, and J.P. Huston The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments Prog. Neurobiol. 50 1996 275 331
56. P. Seeman, F. Ko, M. Willeit, P. McCormick, and N. Ginovart Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors Synapse 58 2005 122 128
57. P. Sokoloff, and J.C. Schwartz Novel dopamine receptors half a decade later Trends Pharmacol. Sci. 16 1995 270 275
58. I. Sora, F.S. Hall, A.M. Andrews, M. Itokawa, X.F. Li, H.B. Wei, C. Wichems, K.P. Lesch, D.L. Murphy, and G.R. Uhl Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference Proc. Natl. Acad. Sci. U. S. A. 98 2001 5300 5305
59. I. Steiner, and I. Wirguin Levodopa addiction in non-parkinsonian patients Neurology 25 2003 1052 1055
60. M. Suzuki, Y.L. Hurd, P. Sokoloff, J.C. Schwartz, and G. Sedvall D3 dopamine receptor mRNA is widely expressed in the human brain Brain Res. 779 1998 58 74
61. T.M. Tzschentke Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues Prog. Neurobiol. 56 1998 613 672
62. T.M. Tzschentke Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade Addict. Biol. 12 2007 227 462
63. S. Thobois, C. Ardouin, E. Lhommée, H. Klinger, C. Lagrange, J. Xie, V. Fraix, M.C. Coelho Braga, R. Hassani, A. Kistner, A. Juphard, E. Seigneuret, S. Chabardes, P. Mertens, G. Polo, A. Reilhac, N. Costes, D. LeBars, M. Savasta, L. Tremblay, J.L. Quesada, J.L. Bosson, A.L. Benabid, E. Broussolle, P. Pollak, and P. Krack Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation Brain 133 2010 1111 1127
64. D.M. Weiner, A.I. Levey, R.K. Sunahara, H.B. Niznik, B.F. O'Dowd, P. Seeman, and M.R. Brann D1 and D2 dopamine receptor mRNA in rat brain Proc. Natl. Acad. Sci. U. S. A. 88 1991 1859 1863
65. D. Weintraub, M. Sohr, M.N. Potenza, A.D. Siderowf, M. Stacy, V. Voon, J. Whetteckey, G.R. Wunderlich, and A.E. Lang Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study Ann. Neurol. 68 2010 963 968
66. R.A. Wise, and M.A. Bozarth A psychomotor stimulant theory of addiction Psychol. Rev. 94 1987 469 492
67. R.A. Wise Dopamine, learning and motivation Nat. Rev. Neurosci. 5 2004 483 494
68. T. Witjas, C. Baunez, J.M. Henry, M. Delfini, J. Regis, A.A. Cherif, J.C. Peragut, and J.P. Azulay Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation Mov. Disord. 20 2005 1052 1055